Published in final edited form as:

Transl Neurosci. 2011 ; 2(3): 256–264.

RECENT DEVELOPMENTS IN NEUROPATHOLOGY OF AUTISM SPECTRUM DISORDERS

Dora Polšek¹, Tomislav Jagatic¹, Maja Cepanec², Patrick R. Hof³, and Goran Šimić^{1,*}

¹University of Zagreb Medical School, Croatian Institute for Brain Research, Zagreb, Croatia

²University of Zagreb, Faculty of Education and Rehabilitation Sciences, Department of Speech and Language Pathology, Zagreb, Croatia

³Fishberg Department of Neuroscience and Friedman Brain Institute, Mount Sinai School of Medicine, New York, USA

Abstract

Autism spectrum disorders (ASD) represent complex neurodevelopmental disorders characterized by impairments in reciprocal social interactions, abnormal development and use of language, and monotonously repetitive behaviors. With an estimated heritability of more than 90%, it is the most strongly genetically influenced psychiatric disorder of the young age. In spite of the complexity of this disorder, there has recently been much progress in the research on etiology, early diagnosing, and therapy of autism. Besides already advanced neuropathologic research, several new technological innovations, such as sleep functional MRI, diffusion tensor imaging (DTI) and proton magnetic resonance spectroscopy imaging (¹H-MRS) divulged promising breakthroughs in exploring subtle morphological and neurochemical changes in the autistic brain. This review provides a comprehensive summary of morphological and neurochemical alterations in autism known to date, as well as a short introduction to the functional research that has begun to advance in the last decade. Finally, we mention the progress in establishing new standardized diagnostic measures and its importance in early recognition and treatment of ASD.

Keywords

Autism; Autism spectrum disorder

INTRODUCTION TO AUTISM

Autism is a neurodevelopmental disorder clinically defined by limited social interactions, abnormal use of language and stereotyped patterns of behavior, interests, and activities [1,2]. It has a prevalence of affecting 1 in 110 children with a 4.5 : 1 male to female ratio [1,3]. The first behavioral signs of social impairment present themselves usually between 1 and 2 years of age and the final diagnosis is usually made by 2–4 years of age [4].

Although the etiology of ASD is still not precisely defined, growing scientific evidence shows a diversity of morphological, functional, genetic, and neurotransmitter systems alterations. However, there are several important obstacles to advances in the search of ASD etiology. As the pathological changes of ASD are developmental, it is imperative to study very young children, preferably in their first three years of life. This is difficult because most

children with ASD do not present with definite signs of social impairment until 24 to 36 months of age, making a precise earlier diagnosis almost impossible [4]. Apart from technical difficulties in forming large-scale study groups of infants and toddlers with precise IQ, age and gender-matched controls, ASD is a very heterogeneous group of disorders, ranging from severely impaired, low-functioning patients to mildly affected children with Asperger's syndrome. According to the current classification, there are three main types of ASD: autistic disorder, Asperger's syndrome, and pervasive developmental disorder - not otherwise specified (PDD-NOS) [5]. Autism is often further subclassified into high-functioning autism (HFA) and low-functioning autism (LFA), based on the IQ level, using an IQ below 70 as the cut-off for LFA and above 70 for HFA [6]. This heterogeneity may explain a great quantity of non-matching research data, most importantly among structural imaging and neuropathologic studies of autism [7,8].

MORPHOLOGICAL FEATURES OF AUTISM

Early brain overgrowth

Early brain overgrowth is one of the most important morphological abnormalities of the autistic brain. The dynamics of the extensive growth of gray and white matter were precisely demonstrated by Courchesne and Pierce in 2005 [9]. At birth, the head circumference of autistic children is normal or slightly smaller than average [9]. After several months, however, the head circumference grows rapidly with an increase of 2 standard deviations or more in 59% of ASD children in contrast to only 6% of normal infants [10]. Also, this acceleration of growth was found to be a good predictor of the severity of clinical outcome and abnormal cerebral and cerebellar volumes in 2 to 5-year-old toddlers [10]. Interestingly, after early increase of brain volume, this process seems to decrease or stop completely, resulting in adult brain volumes of average size [11,12]. The disruption of brain development at an early age has serious implications for the formation of precise circuitry and consequential normal function. At the microstructural level, abnormal cell division and apoptosis regulation, excessive glial growth and inflammation have all been hypothesized as substrates for the disruption of brain development. At the genetic level, there are several genes directly linked with autism, known for their cell growth and migration regulation. The most implicated of these are the *PTEN* and *RELN* genes [76, 86–88] (See Table 1).

Minicolumns

There is important evidence of abnormal minicolumnar structure [13,15] in frontal, temporal, and anterior cingulate cortices. Minicolumns are basic units of cortical information processing, developing and specializing in response to inputs from the environment [14]. The minicolumnar volumes of ASD patients are reduced, but the cell number per minicolumn seems to be normal [14]. This might be explained by a too fast and precocious minicolumnar formation, leaving a shorter time-window for experience-dependent inputs to influence the development of pyramidal neurons of origin of long-distance connections and of their dendritic arbors [9]. Also, an underdevelopment of inhibitory neurons, such as chandelier and basket cells, has been reported, important for isolating specific information processed by a single minicolumn [9]. Lack of inhibition of this kind could lead to hyperactivation of neighboring minicolumns resulting in hyperstimulation by simple outside stimuli which would normally activate one or a small group of minicolumns. On the clinical level this would result in weakened awareness of surrounding context and hyperexcitation by seemingly minor external influences, both often reported as a feature of autism.

Conversely, Casanova *et al.* in 2006 [15] reported an excess of minicolumns, packed closer together. These findings implicate founder cell divisions responsible for the process of

cortical expansion during encephalization [16], placing the time of neurodevelopmental disruption responsible for autism as early as embryonic day 40 [17].

The integrative brain regions

Autism is a disorder primarily affecting high-order integration processes, such as complex social interactions, associative thinking, and appropriate emotional reactions. This has led researchers to focus on brain regions associated with these functions: the frontal and temporal cortex, anterior cingulate cortex (ACC), fusiform gyrus (FG), the amygdala, and the cerebellum.

The frontal cortex

The frontal cortex, specifically its dorsolateral and medial parts, grows disproportionately larger than the rest of the cortex [6] in the first years of life. Afterwards, from 2 to 9 years of age, this portion of the cortex shows an enlargement of only 10% in autistic children opposed to 48% volume increase in the control group [6]. This time coincides precisely with the development of dendritic arbors of pyramidal neurons in layer III, their complex synaptogenesis and the process of myelination [9]. For comparison, there is no evidence of disrupted microarchitecture in the visual cortex, a portion of the brain that finishes development at a dramatic speed in the first months of life [9], leading to a conclusion that the portions of the brain most affected in autism are the same ones that take longest to develop. It is probable that the rapid brain growth in the first year of life prevents later experience to influence the synaptogenesis, cell survival and myelination essential for the formation of higher order functions. Repeating words, social situations or facts shapes and remodels the circuitry of the toddler brain and represents the basis of learning.

Interestingly, the theory of impeded plasticity of integrative brain centers is somewhat in contradiction with the hypothesis of the early disruption of founder cell divisions that form the basis of minicolumnar anomalies found in the frontal and temporal cortices, but not the visual cortex. Namely, the gross number of minicolumns is formed by the early phase of gestation in both frontal and visual cortices alike. The extensive early brain growth might only be a result of a pathological occurrence in early embryonic development and the substrate for the hampered plasticity preventing later advancement. New approaches are needed to research the prenatal brain development, the most feasible being the research of mouse model embryo brains.

Superior temporal and inferior frontal gyri

Investigations of impaired language processing, one of the core deficits of autistic children, have led to several important discoveries. Normally, language processing is a function lateralized to the left hemisphere, involving perisylvian regions of the brain: the superior temporal gyrus (STG) and the inferior frontal gyrus (IFG) [18]. A sleep fMRI study performed by Redcay and Courchesne in 2008 [19] showed anticipated reduced activation in the left STG in response to speech in comparison to mental age-matched subjects, explained by underdevelopment of long-distance connections of this region. Unexpectedly, while listening to a bed-time story, ASD subjects showed greater recruitment of the right STG and IFG in comparison to chronological age controls. Several studies replicated these findings, proving them to be a constant and early feature of autism [20,22]. Toddlers with autism exhibited significantly weaker interhemispheric synchronization (i.e. weak “functional connectivity” across the two hemispheres) in putative language areas; the abnormal right-lateralized language processing was found to be present at as early as 14 months of age [21]. The discovery raises hope that this invariable early characteristic could permit early identification of infants at risk and perhaps be used as a first neurologic functional biomarker for early diagnosing of ASD [20].

The precise substrate for the inverse lateralization of language processing is yet unproven, and it is unclear whether this “wrong-sided” specialization impedes normal language acquirement or is a consequence of an unknown factor preventing development of the left-side lateralization of language. Also, it is possible that the impaired learning of social skills, another core feature of autism, is a result of superseding of the centers for shared attention and gestures, normally centered at the right perisylvian regions [20,22]. Future research, focused on sleep fMRI, will hopefully be able to explain the etiology of these findings.

Weakened emotional processing, one of the most important features of autism, has led researchers to focus on cortical and subcortical regions related to this function, namely the FG, ACC, and amygdala.

Fusiform gyrus

The functional MRI research of the FG has not yet concluded irrevocable results, but most of the findings report present but significantly diminished FG activation in response to face and emotion recognition [23]. For example, in a study by Corbett *et al.* (2009) measuring FG activation in reaction to emotion processing, a significant hypoactivation of both FG was found in the ASD group. In the same study, a “limit” hypoactivation of the FG was found in reaction to face recognition [24]. In differently arranged testing by Pierce and Redcay (2008), hypoactivation of the FG was found only in response to unknown faces, while presenting of familiar faces triggered normal FG activity [25]. This interesting finding has led Pierce to form “the threshold theory” suggesting that ASD patients dispose of normal task-activated networks, but need additional stimuli to activate them [20].

The results of cytoarchitectural research of the FG are also ambiguous. A study, using a rigorous stereologic design, reported reduction in the mean neuron density and mean neuron number, as well as decreased pyramidal cell volumes in layers III and V of FG [26], while others, using a non-stereologic and less systematic approach did not find such changes in this region [27].

Anterior cingulate cortex

The study of ritualistic behavior and impaired social restriction in autism has led researchers to focus on the ACC, a part of the limbic system known for its role in response inhibition tasks, exact delineation between the perception of self and others and error detection [28]. A hypoactivation of the ACC was repeatedly found across task-related fMRI studies such as making judgments about self and others [29], controlling the urge to look towards a suddenly appearing stimulus [30], identifying a wrong letter in an alphabet stream [31] and reacting to unexpected auditory stimuli [32]. Morphological research has also shown substantial aberrations in gray [33] and white matter [34].

ACC is one of the major localizations of von Economo neurons (VEN) in the human brain [35–37]. VENs, or spindle neurons, are large bipolar neurons hypothesized to play a particular role in regulating self-awareness, empathy and understanding of social context, and as such have been implicated in autism pathophysiology [37]. A decreased quantity of VENs has been reported in other disorders affecting emotional conduct and social integration such as frontotemporal dementia [38,39], agenesis of the corpus callosum [40], and early onset schizophrenia [41].

There have been several studies of VENs in autism, and conflicting results have been found. Simms *et al.* (2009) reported two subgroups of autistic patients. Of the 9 autistic patients examined, 3 had substantially elevated VEN density, while 6 others showed a depletion of VENs in the ACC [33]. Another stereologic study by Santos *et al.* (2010) quantified VENs in the ACC and the frontoinsula cortex (FI) of four autistic children [42]. This study

unexpectedly failed to show a similar decrease in VEN numbers. Conversely, an elevated VEN to pyramidal neuron ratio, and an almost significantly higher VEN number was found. Due to a very small number of studied patients, further research will be needed to support these findings. To explicate these counterintuitive results, the authors developed an original outlook on autism, sustained by recent functional imaging data. Autism may not be characterized by severe social isolation and ignorance of social cues, but in fact an impairment of dividing the consciousness of self and others. Surprisingly, both conflicting interpretations result in the same clinical presentation. This theory is supported by the finding that autistic patients show activation of the ventromedial prefrontal cortex in performing self and other-mentalizing tasks, while in healthy individuals this area is operational only in self-referential processing [29,43]. This new interpretation of autism symptoms will perhaps alter the course in autism research.

Amygdala

The amygdala plays an important role in the mediation of social behavior such as, among others, facial and emotional recognition, enhancement of memory for emotionally significant events, predicting reward values [44], and as such has been one of the structures thoroughly studied in autism.

In autistic patients, volumetric analyses show amygdala enlargement as early as age 2, followed by a cessation of growth not proportional, however, to the overall cerebral volume changes [45,46]. Schumann *et al.* (2004) found that although the amygdala in the typically developing boys grows by 40% between 8–18 years of age, the autistic boys present a stagnation of growth [47]. Therefore, even though the amygdala volumes differ significantly in the young age between ASD and control groups, the volumes equalize in the adolescent and adult age groups because of different growth patterns among these two populations. An important correlation was found between the severity of clinical presentation and amygdala volume. Current results also imply that amygdala enlargement is related to a higher degree of anxiety [48] and worse social and communication abilities [49]. Furthermore, different left and right amygdala enlargement was found in correlation with the degree of mental retardation [47]. On the microstructural level, the findings in the amygdala are not consistent [50]. While Schumann and Amaral (2006) found a ~15% decrease in total neuron number in a stereological study of the amygdala [51], prior neuropathological findings reported an increased neuron density [52]. Here too, more stereological studies will be needed to elucidate these contradicting results.

Cerebellum

There has been much research on the cerebellum in autistic patients. Even though the ASD patients do not present typical motor signs of cerebellar dysfunction, knowing that the cerebellum is also involved in cognitive functions, such as language, imitation, attention, and mental imagery [53] has led researchers to designate the cerebellum as an area of interest in autistic patients. Most of the volumetric findings report an augmented size of the cerebellum proportionate to the overall brain volume [50]. The size of the vermis has been reported both as larger and as smaller than normal [54,55] which could be due to the heterogeneity of ASD [56]. In addition, numerous questions have been raised about the method of volumetric measurement of the cerebellar vermis [50], which has been suspected to be subjective and imprecise [57].

Postmortem studies revealed significant abnormalities in the Purkinje cells, particularly in the hemispheres, reporting smaller cell size and decreased cell-packing density [50,57]. Even though the Purkinje cell irregularities are one of the most consistent morphological findings in autism thus far, these reports have not yet been confirmed by stereological

research. Furthermore, in most of the post-mortem studies, the brains were obtained from individuals with mental retardation associated with ASD, while most of the volumetric studies have been performed on high-functioning individuals with autism [50].

White matter

Studies of cerebral white matter in ASD patients report changes in organization, maturation rate, and structural integrity [12, 58–60]. Some of these studies use the technology of diffusion tensor imaging (DTI), a MRI technique that enables the measurement of the restricted diffusion of water in tissue in order to produce neural tract images. To assess the fiber density, axonal diameter and myelination stage, a parameter called fractional anisotropy (FA) is measured. In a recent study by Shukla *et al.* (2010) [61] structural changes in FA were observed in several cortical regions involved in social cognition and information integration as well as in interhemispheric and corticosubcortical white matter tracts such as the corpus callosum, anterior and posterior limbs of the internal capsule, cingulum, anterior thalamic radiation, and corticospinal tract. Most studies of white matter in ASD are consistent with the finding of decreased FA in regions performing higher cognitive functions, interpreted as lower fiber density, smaller axonal diameter and uneven myelination phases. One of the studies found the largest aberration FA values in the anterior cingulate cortex [34], a region associated with anticipating conflicting information and interpretation of subtle emotional subtexts [28]. In contrast, Noriuchi *et al.* (2010) [34] also found an excess of white matter in cerebellar vermis lobules, a region also known for its abnormal cytoarchitecture in autism (see above).

NEUROCHEMICAL FINDINGS

In a search for a specific and sensitive biomarker of autism, a great quantity of research has focused on the study of neurotransmitters, measuring their blood concentrations, marking receptor density and quantifying the production and degradation of specific neurochemicals. The proton magnetic resonance spectroscopy imaging (¹H-MRS), a technique permitting non-invasive quantification of endogenous neurochemicals, has provided useful information, none of which unfortunately provided a firm and conclusive theory.

However, one of the most important neurochemical theories of autism supported by diverse different research approaches is the excitation/inhibition imbalance theory. Based on extensive evidence of glutamate-and GABA-related abnormalities found in the autistic brain, it has been hypothesized that a complex lack of local inhibition and long-distance excitation during development and later in life could be a common factor to the diverse developmental findings in autism.

One of the first findings that pointed to an excitation/inhibition dysregulation in autism was the fact that around 30% of patients with ASD develop epileptic seizures during their lifetime and approximately 60% have epileptiform EEG activity during sleep [62,63]. Also, as noted above, an underdevelopment of inhibitory neurons, allowing the processing of individual stimuli, has been found in several brain areas [9].

There is evidence of glutamate dysregulation in the ASD population, although none point to a single gene or protein in the glutamate signaling system, but indicate a complex pathophysiology in the functioning of this neurotransmitter in general. Aldred *et al.* (2003) measured glutamate blood levels in ASD patients and their families and found higher than normal concentrations [64]. In the same study the peripheral levels of phenylalanine, lysine and asparagine were also elevated, while glutamine concentration was reduced. Moreno-Fuyenmayor *et al.* (1996) also found lower blood levels of glutamine [65] but Shinohe *et al.* (2006) [66] failed to observe reduced glutamine concentration. Both studies found higher

glutamate blood levels, and the latter reported a significant correlation between the glutamate upregulation and the severity of clinical presentation. In conclusion, the peripheral levels of glutamate are definitely altered in relation to autism, but measuring neurochemical blood levels is perhaps too dependent on pre-medication, nutrition and comorbidity as to be a reliable marker of autism.

Secondly, the research of glutamate system related genes has shown some substantial aberrations. An upregulation of AMPA receptor subunits GluR1, GluR2 and GluR3 were found through cDNA and mRND quantification in post-mortem cerebellar and hippocampal tissue, but interestingly, a lower overall AMPA receptor density was reported in the same cerebellar samples [67]. An excess of transmission of maternal haplotype for another glutamate receptor, GluR6 was found by Jamain *et al.* (2002) and confirmed later in a large scale study on 174 parents-child trios [68].

An additional parent-of-origin specific region, the 15q12 was found to have significant association with autism susceptibility [69]. This region contains a cluster of GABA(A) receptor subunit genes (GABRB3, GABRA5, and GABRG3), again pointing to the excitation/inhibition dysregulation theory. Duplications in this region have been reported and confirmed in numerous studies of autism [69–71]. A quantification of GABRA1–3 and GABRB3 receptors in the cerebellum and frontal and parietal cortex by Fatemi *et al.* (2009) showed decreased receptor density. The parietal GABA receptor density was reduced for all quantified receptors, while other results varied with receptor type and localization [72]. Also, a reduced GABRB density was found in ACC and FG [73], areas known for morphological alterations in autism [23–37, 42].

Glutamate decarboxylase (GAD), an enzyme that metabolizes glutamate into GABA, was also found to be significantly reduced in the parietal cortex and cerebellum of ASD patients [74], thus showing that both neurotransmitter systems are inseparable in the etiology of autism.

A recent ¹H-MRS study by Bernardi *et al.* (2011) has measured concentrations of neurotransmitters in varying brain regions in high-functioning, non-medicated adults with autism and controls. Unfortunately, ¹H-MRS cannot yet distinct between glutamate, glutamine, and GABA signals, so these compounds are measured together and termed Glx. However, a significant depletion of Glx concentration was found in ACC in this study, providing important evidence for the glutamate-GABA dysregulation theory. Although only high-functioning patients were used in the study, no IQ correlation was noted, implicating that this finding can be generalized to the whole ASD population [75].

Further neurochemical imbalances were found in other ¹H-MRS studies, such as widespread and localized reductions of *N*-acetyl-aspartate, choline-containing compounds and myo-inositol concentrations, but more studies of this type will be needed to support these findings. The precise ¹H-MRS technology will surely prove to be very useful in the future.

A large quantity of genetic research has also implicated that the genes involved in some ASD cases are also connected to the excitation/inhibition imbalance. There is a subgroup of genes conclusively linked to autism, which, through regulation of synaptic plasticity and receptor expression, mediate the metabolism of glutamate and GABA, thus resulting in ASD-like symptoms. The genes most implicated are *SHANK3*, neuroligin 3 (*NL3*) and 4 (*NL4*), *GABRB3* and *FMR1* [72,76–88] (See Table 1).

Serotonin

Serotonin (5HT) dysregulation has been mentioned as a possible etiology of autism, based on consistent findings of higher than normal blood levels of 5HT [89]. Hyperserotonemia has been reported in about a third of all the autistic patients, but a correlation between severity of clinical presentation and levels of 5HT has not been established. The elevated blood levels of autistic patients seem to be age-independent, while normally developing children show a progressive decrease in 5HT blood levels [89]. The increased concentration of 5HT is also found in parents and siblings of ASD patients with hyperserotonemia [89,90]. Some findings report a negative influence of high 5HT levels on language learning [91] and self-injuring behavior [92] as well as IQ levels [89]. Symptoms of autism comorbidities such as depression, irritability and obsessive-compulsive disorder have been shown to improve with selective 5HT reuptake inhibitors (SSRI) therapy [68]. 5HT plays an important role in early brain development when serving as a growth factor and regulating proliferation and maturation, both key events known to be disrupted in autism, which makes it a possible primary defect in ASD etiology [68].

Dopamine

Research on dopamine in autism was motivated based on clinical evidence showing reduced aggressive, hyperactive and self-destructing behavior in patients under treatment with dopamine D² receptor antagonists. This amelioration of symptoms has been attributed to D²-mediated glutamate release, again pointing to the excitation/inhibition imbalance theory [75]. The peripheral quantification of homovanilic acid (HVA), a metabolite of dopamine, has proven to be insignificantly altered in autism. Furthermore, central HVA measurements were inconstant, showing evidence of elevated, normal or lowered concentrations. Studies of endogenous opioids and norepinephrine in autism have also failed to show conclusive results [68].

Neuropeptides

Finally, two neuropeptides, vasopressin (AVP) and especially oxytocin (OT) have been suspected to be involved in the pathophysiology of ASD. OT and AVP are similar nonapeptides produced in the hypothalamus and secreted from the pituitary. Oxytocin plays crucial roles during child birth, breastfeeding and sexual arousal [93–95]. Perhaps even more importantly, research performed on knock-out OT mice has confirmed it to be vital in mother-child bonding, pair-bonding, as well as in social recognition and attachment behavior (trustfulness) in general, thus giving OT dysregulation a possible role in the etiology of autism [96–98]. The hypothesis that autistic children are affected by a prolonged exposure to OT during birth leading to a downregulation of OT receptors has been refuted [99]. However, decreased plasma concentration of OT in ASD patients has been reported, providing an interesting explanation of the male: female ratio in patients with autism. A higher female sensitivity to OT could prevent the development of autistic traits in females, while the same decrease of OT concentration could lead to symptoms of ASD in males [68,100].

DISCUSSION

ASD is clinically still a poorly defined and incurable disease. This is mostly due to the fact that ASD is a group of disorders characterized by its heterogeneity. Low-functioning autism, distinguished by its severe mental retardation, can be easily mistaken for another syndromic disorder or isolated retardation. On the other hand, high-functioning autism and Asperger's syndrome are the object of an ongoing argument questioning the distinction between the two. Some postulate that an apprehension of phrase language development before 36 months of age is a valid distinction between the two syndromes [101], while others emphasize the

diagnostic overlap between high-functioning autism and Asperger's syndrome. The diversity of ASD can explain the contradictory findings of morphological, neurochemical, and genetic research. This fact invokes an urging need to synthesize all present findings into a coherent compendium of knowledge and try to accurately define all the permutations of this complex disorder, a task begun by the Autism Genetic Resource Exchange. A fast progressing understanding of genes implicated in synaptogenesis and plasticity, such as *SHANK3*, *NL3* and *NL4* or *NEUREXIN1* 1 provides evidence that autism is a disease with high potential for improvement with active behavioral therapy. The investigation of different genes associated with neurotransmitter systems, for example *GABRB3* and *FMR1*, has already started to produce promising results at the level of pharmacological therapy.

Even though there is no cure yet available for autism, there has been a lot of effort put into early diagnosing of ASD patients. This is a difficult project because normal and affected infants do not necessarily differ in the first year of development. In addition, a high comorbidity rate in autism patients, as well as the diversity of clinical presentation complicates precise and timely identification.

Lately, there has been an important development of early screening for ASD. A new version of Autism Diagnostic Observation Schedule (ADOS) has been adapted for children between 12 and 30 months of age, promising precocious recognition of ASD patients and a possibility of early intervention [102]. Moreover, a One-year Well Baby Check-up Approach has been developed for screening in the general population, showing a encouraging positive predictive value of 0.75 [103]. Future research should be orientated to providing a specific and sensitive biomarker of ASD patients which, paired with screening behavioral tests, could easily lead to an accurate early diagnosing of ASD [104]. Abnormal lateralization in response to language, a measurement of blood amino acids and neurotransmitters or a discovery of another distinctive ASD trait will hopefully find its role in clinical assessment of autism in the future.

Acknowledgments

This work was supported by NIH grant MH093725, and by Autism Speaks, the James S. McDonnell Foundation, and the Seaver Foundation (to P.R.H.) and by the Ministry of Science, Education and Sports of the Republic of Croatia (grant no. 108-1081870-1942 to G.Š.).

References

1. Bailey A, Phillips W, Rutter M. Autism: towards an integration of clinical, genetic, neuropsychological, and neurobiological perspectives. *J Child Psychol Psychiatry*. 1996; 37:89–126. [PubMed: 8655659]
2. Amaral DG, Schumann CM, Wu Nordahl C. Neuroanatomy of autism. *Trends in Neuroscience*. 2008; 31:137–145.
3. Rice C. Prevalence of Autism Spectrum Disorders - Autism and Developmental Disabilities Monitoring Network, United States, 2006. *MMWR Surveill Summ*. 2009; 58:1–20.
4. Courchesne E, Pierce K, Schumann CM, Redcay E, Buckwalter JA, Kennedy DP, Morgan J. Mapping Early Brain Development in Autism. *Neuron*. 2007; 56:399–413. [PubMed: 17964254]
5. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 4. 1994.
6. Carper R, Courchesne E. Localized enlargement of the frontal lobe in autism. *Biol Psychiatry*. 2005; 57:126–133. [PubMed: 15652870]
7. Palmen SJMC, van Engeland H. Review on structural neuroimaging findings in autism. *J Neural Transm*. 2004; 111:903–929. [PubMed: 15206006]
8. Palmen SJ, van Engeland H, Hof PR, Schmitz C. Neuropathological findings in autism. *Brain*. 2004; 127(Pt 12):2572–83. [PubMed: 15329353]

9. Courchesne E, Pierce K. Brain overgrowth in autism during a critical time in development: implications for frontal pyramidal neuron and interneuron development and connectivity. *Int J Dev Neurosci.* 2005; 23:153–170. [PubMed: 15749242]
10. Courchesne E, Carper R, Akshoomoff N. Evidence of brain overgrowth in the first year of life in autism. *JAMA.* 2003; 290:337–344. [PubMed: 12865374]
11. Carper RA, Moses P, Tigue ZD, Courchesne E. Cerebral lobes in autism: early hyperplasia and abnormal age effects. *Neuroimage.* 2002; 16:1038–1051. [PubMed: 12202091]
12. Herbert MR, Ziegler DA, Deutsch CK, O'Brien LM, Lange N, Bakardjiev A, et al. Dissociations of cerebral cortex, subcortical and cerebral white matter volumes in autistic boys. *Brain.* 2003; 126:1182–1192. [PubMed: 12690057]
13. Casanova MF, Buxhoeveden DP, Switala AE, Roy E. Minicolumnar pathology in autism. *Neurology.* 2002; 58:428–432. [PubMed: 11839843]
14. Lücke J, von der Malsburg C. Rapid processing and unsupervised learning in a model of the cortical macrocolumn. *Neural Comput.* 2004; 16:501–533. [PubMed: 15006090]
15. Casanova MF, van Kooten IAJ, Switala AE, van Engeland H, Heinsen H, Steinbusch HWM, et al. Minicolumnar abnormalities in autism. *Acta Neuropathol.* 2006; 112:287–303. [PubMed: 16819561]
16. Rakic P. A small step for the cell, a giant leap for mankind: a hypothesis of neocortical expansion during evolution. *Trends Neurosci.* 1995; 18:383–388. [PubMed: 7482803]
17. Rakic P. Limits of neurogenesis in primates. *Science.* 1985; 227:1054–1056. [PubMed: 3975601]
18. Dehaene-Lambertz G, Hertz-Pannier L, Dubois J. Nature and nurture in language acquisition: anatomical and functional brain-imaging studies in infants. *Trends Neurosci.* 2006; 29:367–373. [PubMed: 16815562]
19. Redcay E, Courchesne E. Deviant functional magnetic resonance imaging patterns of brain activity to speech in 2–3-year-old children with autism spectrum disorder. *Biol Psychiatry.* 2008; 64:589–598. [PubMed: 18672231]
20. Pierce K. Early functional brain development in autism and the promise of sleep fMRI. *Brain Res.* 2010; 1380:162–174. [PubMed: 20869953]
21. Dinstein I, Pierce K, Eyler L, Solso S, Malach R, Behrmann M, et al. Disrupted neural synchronization in toddlers with autism. *Neuron.* 2011; 70:1218–1225. [PubMed: 21689606]
22. Knaus TA, Silver AM, Kennedy M, Lindgren KA, Dominick KC, Siegel J, et al. Language laterality in autism spectrum disorder and typical controls: a functional, volumetric, and diffusion tensor MRI study. *Brain Lang.* 2010; 112:113–120. [PubMed: 20031197]
23. Kleinhans NM, Richards T, Johnson LC, Weaver KE, Greenson J, Dawson G, et al. fMRI evidence of neural abnormalities in the subcortical face processing system in ASD. *Neuroimage.* 2011; 54:697–704. [PubMed: 20656041]
24. Corbett B, Carmeana V, Ravizzae S, Wendelkenf C, Henryg ML, Cartera C, et al. A functional and structural study of emotion and face processing in children with autism. *Psychiatry Res.* 2009; 173:196–205. [PubMed: 19665877]
25. Pierce K, Redcay E. Fusiform function in children with an autism spectrum disorder is a matter of “who”. *Biol Psychiatry.* 2008; 64:552–602. [PubMed: 18621359]
26. van Kooten IA, Palmen SJ, von Cappeln P, Steinbusch HW, Korrr H, Heinsen H, Hof PR, van Engeland H, Schmitz C. Neurons in the fusiform gyrus are fewer and smaller in autism. *Brain.* 2008; 131:987–999. [PubMed: 18332073]
27. Oblak AL, Rosene DL, Kemper TL, Bauman ML, Blatt GJ. Altered posterior cingulate cortical cytoarchitecture, but normal density of neurons and interneurons in the posterior cingulate cortex and fusiform gyrus in autism. *Autism Res.* 2011; 4:200–211. [PubMed: 21360830]
28. Bush G, Luu P, Posner MI. Cognitive and emotional influences in anterior cingulate cortex. *Trends Cogn Sci.* 2000; 4:215–222. [PubMed: 10827444]
29. Kennedy DP, Courchesne E. Functional abnormalities of the default network during self- and other-reflection in autism. *Soc Cogn Affect Neurosci.* 2008; 3:177–190. [PubMed: 19015108]
30. Agam Y, Joseph RM, Barton JJ, Manoach DS. Reduced cognitive control of response inhibition by the anterior cingulate cortex in autism spectrum disorders. *Neuroimage.* 2010; 52:336–347. [PubMed: 20394829]

31. Kana RK, Keller TA, Minshew NJ, Just MA. Inhibitory control in high-functioning autism: decreased activation and underconnectivity in inhibition networks. *Biol Psychiatry*. 2007; 62:198–206. [PubMed: 17137558]
32. Gomot M, Bernard FA, Davis MH, Belmonte MK, Ashwin C, Bullmore ET, et al. Change detection in children with autism: an auditory event-related fMRI study. *Neuroimage*. 2006; 29:475–84. [PubMed: 16115783]
33. Simms ML, Kemper TL, Timbie CM, Bauman ML, Blatt GJ. The anterior cingulate cortex in autism: heterogeneity of qualitative and quantitative cytoarchitectonic features suggests possible subgroups. *Acta Neuropathol*. 2009; 118:673–84. [PubMed: 19590881]
34. Noriuchi M, Kikuchi Y, Yoshiura T, Kira R, Shigeto H, Hara T, et al. Altered white matter fractional anisotropy and social impairment in children with autism spectrum disorder. *Brain Res*. 2010; 1362:141–149. [PubMed: 20858472]
35. Nimchinsky EA, Vogt BA, Morrison JH, Hof PR. Spindle neurons of the human anterior cingulate cortex. *J Comp Neurol*. 1995; 355(1):27–37. [PubMed: 7636011]
36. Nimchinsky EA, Gilissen E, Allman JM, Perl DP, Erwin JM, Hof PR. A neuronal morphologic type unique to humans and great apes. *Proc Natl Acad Sci U S A*. 1999; 96(9):5268–73. [PubMed: 10220455]
37. Allman JM, Tetreault NA, Hakeem AY, Manaye KF, Semendeferi K, Erwin JM, Park S, Goubert V, Hof PR. The von Economo neurons in frontoinsular and anterior cingulate cortex in great apes and humans. *Brain Struct Funct*. 2010; 214(5–6):495–517. [PubMed: 20512377]
38. Seeley WW, Carlin DA, Allman JM, Macedo MN, Bush C, Miller BL, DeArmond SJ. Early frontotemporal dementia targets neurons unique to apes and humans. *Ann Neurol*. 2006; 60(6):660–7. [PubMed: 17187353]
39. Kim EJ, Sidhu M, Gaus SE, Huang EJ, Hof PR, Miller BL, Dearmond SJ, Seeley WW. Selective frontoinsular von Economo neuron and fork cell loss in early behavioral variant frontotemporal dementia. *Cereb Cortex*. 2011 in press.
40. Paul LK, Schieffer B, Brown WS. Social processing deficits in agenesis of the corpus callosum: narratives from the Thematic Appreciation Test. *Arch Clin Neuropsychol*. 2004; 19:215–225. [PubMed: 15010087]
41. Brüne M, Schobel A, Karau R, Benali A, Faustmann PM, Juckel G, et al. von Economo neuron density in the anterior cingulate cortex is reduced in early onset schizophrenia. *Acta Neuropathol*. 2010; 119:771–778. [PubMed: 20309567]
42. Santos M, Uppal N, Butti C, Wicinski B, Schmeidler J, Giannakopoulos P, et al. von Economo neurons in autism: a stereologic study of the frontoinsular cortex in children. *Brain Res*. 2011; 1380:206–217. [PubMed: 20801106]
43. Lombardo MV, Baron-Cohen S. Unraveling the paradox of the autistic self. *Wiley Interdiscipl Rev Cogn Sci*. 2010; 1:393–403.
44. Adolphs R. The neurobiology of social recognition. *Curr Opin Neurobiol*. 2001; 11:231–239. [PubMed: 11301245]
45. Sparks BF, Friedman SD, Shaw DW, Aylward EH, Echelard D, Artru AA, et al. Brain structural abnormalities in young children with autism spectrum disorder. *Neurology*. 2002; 59:184–192. [PubMed: 12136055]
46. Schumann CM, Nordahl CW. Bridging the gap between MRI and postmortem research in autism. *Brain Res*. 2011; 1380:175–86. [PubMed: 20869352]
47. Schumann CM, Hamstra J, Goodlin-Jones BL, Lotspeich LJ, Kwon H, Buonocore MH, et al. The amygdala is enlarged in children but not adolescents with autism; the hippocampus is enlarged at all ages. *J Neurosci*. 2004; 24:6392–6401. [PubMed: 15254095]
48. Juranek J, Filipek PA, Berenji GR, Modahl C, Osann K, Spence MA. Association between amygdala volume and anxiety level: magnetic resonance imaging (MRI) study in autistic children. *J Child Neurol*. 2006; 21:1051–1058. [PubMed: 17156697]
49. Munson J, Dawson G, Abbott R, Faja S, Webb SJ, Friedman SD, et al. Amygdalar volume and behavioral development in autism. *Arch Gen Psychiatry*. 2006; 63:686–669. [PubMed: 16754842]
50. Amaral DG, Schumann CM, Nordahl CW. Neuroanatomy of autism. *Trends Neurosci*. 2008; 31:137–45. [PubMed: 18258309]

51. Schumann CM, Amaral DG. Stereological analysis of amygdala neuron number in autism. *J Neurosci*. 2006; 26:7674–7679. [PubMed: 16855095]
52. Kemper TL, Bauman ML. The contribution of neuropathologic studies to the understanding of autism. *Neurol Clin*. 1993; 11:175–187. [PubMed: 8441369]
53. Schmahmann JD. An emerging concept. The cerebellar contribution to higher function. *Arch Neurol*. 1991; 48:1178–87. [PubMed: 1953406]
54. Courchesne E, Saitoh O, Townsend JP, Yeung-Courchesne R, Press GA, Lincoln AJ, et al. Cerebellar hypoplasia and hyperplasia in infantile autism. *Lancet*. 1994; 343:63–64. [PubMed: 7905084]
55. Stanfield AC, McIntosh AM, Spencer MD, Philip R, Gaur S, Lawrie SM. Towards a neuroanatomy of autism: a systematic review and meta-analysis of structural magnetic resonance imaging studies. *Eur Psychiatry*. 2008; 23:289–299. [PubMed: 17765485]
56. Piven J, Saliba K, Bailey J, Arndt S. An MRI study of autism: the cerebellum revisited. *Neurology*. 1997; 49:546–551. [PubMed: 9270594]
57. Scott JA, Schumann CM, Goodlin-Jones BL, Amaral DG. A comprehensive volumetric analysis of the cerebellum in children and adolescents with autism spectrum disorder. *Autism Res*. 2009; 2:246–57. [PubMed: 19885834]
58. Hazlett HC, Poe MD, Gerig G, Gimpel Smith R, Piven J. Cortical gray and white brain tissue volume in adolescents and adults with autism. *Biol Psychiatry*. 2006; 59:1–6. [PubMed: 16139816]
59. Barea-Goraly N, Kwon H, Menon V, Eliez S, Lotspeich L, Reis AL. White matter structure in autism: preliminary evidence from diffusion tensor imaging. *Biol Psychiatry*. 2004; 55:323–326. [PubMed: 14744477]
60. Bashat DB, Kronfeld-Duenias V, Zachor DA, Ekstein PM, Hendler T, Tarrasch R, et al. Accelerated maturation of white matter in young children with autism: A high b value DWI study. *Neuroimage*. 2007; 37:40–47. [PubMed: 17566764]
61. Shukla DK, Keehn B, Müller RA. Tract-specific analyses of diffusion tensor imaging show widespread white matter compromise in autism spectrum disorder. *J Child Psychol Psychiatry*. 2011; 52:286–295. [PubMed: 21073464]
62. Spence SJ, Schneider MT. The role of epilepsy and epileptiform EEGs in autism spectrum disorders. *Pediatr Res*. 2009; 65:599–606. [PubMed: 19454962]
63. Chez MG, Chang M, Krasne V, Coughlan C, Kominsky M, Schwartz A. Frequency of epileptiform EEG abnormalities in a sequential screening of autistic patients with no known clinical epilepsy from 1996 to 2005. *Epilepsy Behav*. 2006; 8:267–271. [PubMed: 16403678]
64. Aldred S, Moore KM, Fitzgerald M, Waring RH. Plasma amino acid levels in children with autism and their families. *J Autism Dev Disord*. 2003; 33:93–97. [PubMed: 12708584]
65. Moreno-Fuenmayor H, Borjas L, Arrieta A, Valera V, Socorro-Candanoza L. Plasma excitatory amino acids in autism. *Invest Clin*. 1996; 37:113–128. [PubMed: 8718922]
66. Shinohe A, Hashimoto K, Nakamura K, Tsujii M, Iwata Y, Tsuchiya KJ, et al. Increased serum levels of glutamate in adult patients with autism. *Prog Neuropsychopharmacol Biol Psychiatry*. 2006; 30:1472–1477. [PubMed: 16863675]
67. Purcell AE, Jeon OH, Zimmerman AW, Blue ME, Pevsner J. Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. *Neurology*. 2001; 57:1618–1628. [PubMed: 11706102]
68. McDougale CJ, Erickson CA, Stigler KA, Posey DJ. Neurochemistry in the pathophysiology of autism. *J Clin Psychiatry*. 2005; (Suppl 10):9–18. [PubMed: 16401145]
69. McCauley JL, Olson LM, Delahanty R, Amin T, Nurmi EL, Organ EL, et al. A linkage disequilibrium map of the 1-Mb 15q12 GABA(A) receptor subunit cluster and association to autism. *Am J Med Genet*. 2004; 131B:51–59. [PubMed: 15389768]
70. Hogart A, Wu D, LaSalle JM, Schanen NC. The comorbidity of autism with the genomic disorders of chromosome 15q11.2-q13. *Neurobiol Dis*. 2010; 38:181–191. [PubMed: 18840528]
71. Nurmi EL, Amin T, Olson LM, Jacobs MM, McCauley JL, Lam AY, et al. Dense linkage disequilibrium mapping in the 15q11-q13 maternal expression domain yields evidence for association in autism. *Mol Psychiatry*. 2003; 8:624–634. [PubMed: 12851639]

72. Fatemi SH, Reutiman TJ, Folsom TD, Thuras PD. GABA(A) receptor downregulation in brains of subjects with autism. *J Autism Dev Disord.* 2009; 39:223–230. [PubMed: 18821008]
73. Oblak AL, Gibbs TT, Blatt GJ. Decreased GABA(B) receptors in the cingulate cortex and fusiform gyrus in autism. *J Neurochem.* 2010; 114:1414–1423. [PubMed: 20557420]
74. Fatemi SH, Halt AR, Stary JM, Kanodia R, Schulz SC, Realmuto GR. Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices. *Biol Psychiatry.* 2002; 52:805–810. [PubMed: 12372652]
75. Bernardi S, Anagnostou E, Shen J, Kolevzon A, Buxbaum JD, Hollander E, et al. In vivo ¹H-magnetic resonance spectroscopy study of the attentional networks in autism. *Brain Res.* 2011; 1380:198–205. [PubMed: 21185269]
76. Ey E, Leblond CS, Bourgeron T. Behavioral profiles of mouse models for autism spectrum disorders. *Autism Res.* 2011; 4:5–16. [PubMed: 21328568]
77. Bangash MA, Park JM, Melnikova T, Wang D, Jeon SK, Lee D, et al. Enhanced polyubiquitination of Shank3 and NMDA receptor in a mouse model of autism. *Cell.* 2011; 145:758–72. [PubMed: 21565394]
78. Peça J, Feliciano C, Ting JT, Wang W, Wells MF, Venkatraman TN, et al. Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. *Nature.* 2011; 472:437–442. [PubMed: 21423165]
79. Bozdagi O, Sakurai T, Papapetrou D, Wang X, Dickstein DL, Takahashi N, et al. Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication. *Mol Autism.* 2010; 1:15. [PubMed: 21167025]
80. Ellegood J, Lerch JP, Henkelman RM. Brain abnormalities in a Neuroligin3 R451C knockin mouse model associated with autism. *Autism Res.* 2011; 1002/aur.215
81. Gutierrez RC, Hung J, Zhang Y, Kertesz AC, Espina FJ, Colicos MA. Altered synchrony and connectivity in neuronal networks expressing an autism-related mutation of neuroligin 3. *Neuroscience.* 2009; 162:208–21. [PubMed: 19406211]
82. Etherton MR, Tabuchi K, Sharma M, Ko J, Südhof TC. An autism-associated point mutation in the neuroligin cytoplasmic tail selectively impairs AMPA receptor-mediated synaptic transmission in hippocampus. *EMBO J.* 2011; 30:2908–2919. [PubMed: 21642956]
83. Testa-Silva G, Loebel A, Giugliano M, de Kock CP, Mansvelder HD, Meredith RM. Hyperconnectivity and slow synapses during early development of medial prefrontal cortex in a mouse model for mental retardation and autism. *Cereb Cortex.* 2011 Aug 19. [Epub ahead of print]. 10.1093/cercor/bhr224
84. Hagerman R, Au J, Hagerman P. FMR1 premutation and full mutation molecular mechanisms related to autism. *J Neurodev Dis.* 2011; 3:211–224.
85. DeLorey TM, Sahbaie P, Hashemi E, Li WW, Salehi A, Clark DJ. Somatosensory and sensorimotor consequences associated with the heterozygous disruption of the autism candidate gene, Gabrb3. *Behav Brain Res.* 2011; 216:36–45. [PubMed: 20699105]
86. Fatemi SH. Co-occurrence of neurodevelopmental genes in etiopathogenesis of autism and schizophrenia. *Schizophr Res.* 2010; 118:303–304. [PubMed: 20153953]
87. Holt R, Barnby G, Maestrini E, Bacchelli E, Brocklebank D, Sousa I, et al. Linkage and candidate gene studies of autism spectrum disorders in European populations, EU Autism MOLGEN Consortium. *Eur J Hum Genet.* 2010; 18:1013–1019. [PubMed: 20442744]
88. McBride KL, Varga EA, Pastore MT, Prior TW, Manickam K, Atkin JF, et al. Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly. *Autism Res.* 2010; 3:137–141. [PubMed: 20533527]
89. Leboyer M, Philippe A, Bouvard M, Guilloud-Bataille M, Bondoux D, Tabuteau F, et al. Whole blood serotonin and plasma beta-endorphin in autistic probands and their first-degree relatives. *Biol Psychiatry.* 1999; 45:158–163. [PubMed: 9951562]
90. Cook EH Jr, Leventhal BL, Freedman DX. Free serotonin in plasma: autistic children and their first-degree relatives. *Biol Psychiatry.* 1988; 24:488–491. [PubMed: 3408767]
91. Hranilovic D, Bujas-Petkovic Z, Vragovic R, Vuk T, Hock K, Jernej B. Hyperserotonemia in adults with autistic disorder. *J Autism Dev Disord.* 2007; 37:1934–1940. [PubMed: 17165147]

92. Kolevzon A, Newcorn JH, Kryzak L, Chaplin W, Watner D, Hollander E, et al. Relationship between whole blood serotonin and repetitive behaviors in autism. *Psychiatry Res.* 2010; 175:274–276. [PubMed: 20044143]
93. Brunton PJ, Russell JA. The expectant brain: adapting for motherhood. *Nat Rev Neurosci.* 2008; 9(1):11–25. [PubMed: 18073776]
94. Neumann ID. Brain oxytocin: a key regulator of emotional and social behaviours in both females and males. *J Neuroendocrinol.* 2008; 20(6):858–65. [PubMed: 18601710]
95. Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. *Nat Rev Neurosci.* 2011; 12(9):524–38.10.1038/nrn3044 [PubMed: 21852800]
96. Insel TR, O'Brien DJ, Leckman JF. Oxytocin, vasopressin, and autism: is there a connection? *Biol Psychiatry.* 1999; 45:145–157. [PubMed: 9951561]
97. Ferguson JN, Young LJ, Hearn EF, Matzuk MM, Insel TR, Winslow JT. Social amnesia in mice lacking the oxytocin gene. *Nat Genet.* 2000; 25:284–288. [PubMed: 10888874]
98. Šešo-Šimić Đ, Sedmak G, Hof PR, Šimić G. Recent advances in the neurobiology of attachment behavior. *Transl Neurosci.* 2010; 2:148–159.
99. Gale S, Ozonoff S, Lainhart J. Brief report: pitocin induction in autistic and nonautistic individuals. *J Autism Dev Disord.* 2003; 33:205–208. [PubMed: 12757361]
100. Insel TR. A neurobiological basis of social attachment. *Am J Psychiatry.* 1997; 154:726–735. [PubMed: 9167498]
101. Lotspeich LJ, Kwon H, Schumann CM, Fryer SL, Goodlin-Jones BL, Buonocore MH, et al. Investigation of neuroanatomical differences between autism and Asperger syndrome. *Arch Gen Psychiatry.* 2004; 61:291–298. [PubMed: 14993117]
102. Luyster R, Gotham K, Guthrie W, Coffing M, Petrak R, Pierce K, et al. The autism diagnostic observation schedule-toddler module: a new module of a standardized diagnostic measure for autism spectrum disorders. *J Autism Dev Disord.* 2009; 39:1305–1320. [PubMed: 19415479]
103. Pierce K, Carter C, Weinfeld M, Desmond J, Hazin R, Bjork R, et al. Detecting, studying, and treating autism early: the one-year well-baby check-up approach. *J Pediatr.* 2011; 159:458–465. [PubMed: 21524759]
104. Uppal N, Papapetrou D, Santos M, Bozdagi O, Buxbaum JD, Hof PR. Autism spectrum disorders: neuropathology and animal models. *Envir Health Perspect.* submitted.

Table 1

The list of selected genes associated with the autistic spectrum disorders.

Gene	Function	Recent relevant studies
<i>RELN</i>	Regulates neuronal migration and positioning in the developing brain by controlling cell–cell interactions	Fatemi, 2010 [86] Holt <i>et al.</i> 2010 [87]
<i>PTEN</i>	Tumor suppressor gene, regulating the cell cycle	Ey <i>et al.</i> 2011[76] McBride <i>et al.</i> 2010 [88]
<i>SHANK3</i>	Mediates synapse formation and dendritic spine maturation, connects neurotransmitter receptors	Bangash <i>et al.</i> 2011[77] Peça <i>et al.</i> 2011 [78] Bozdagi <i>et al.</i> 2010 [79]
<i>NL3</i>	Mediates synapse formation and remodeling	Ellegood <i>et al.</i> 2011[80] Gutierrez <i>et al.</i> 2009 [81]
<i>NL4</i>	Mediates synapse formation and remodeling	Etherton <i>et al.</i> 2011 [82] Ey <i>et al.</i> 2011 [76]
<i>FMR1</i>	Regulation of synaptic plasticity	Testa-Silva <i>et al.</i> 2011 [83] Hagerman <i>et al.</i> 2011 [84]
<i>GABRB3</i>	Part of GABA-A receptor	DeLorey <i>et al.</i> 2011 [85] Fatemi <i>et al.</i> 2009 [72]